|
Alfuzosin
resources
|
|
|
|
|
|
DRUG INFO
Alfuzosin
Drug Name:
Alfuzosin
Indication: For the treatment of the signs and symptoms of benign prostatic hyperplasia
Pharmacology: Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Alfuzosin results from a decrease in systemic vascular resistance and the parent compound Alfuzosin is primarily responsible for the antihypertensive activity.
Mechanism Of Action: Alfuzosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Drug Category: Antihypertensive Agents; Unclassified Therapeutic Agents (92:00.00); ATC:G04CA01
Brand Names/Synonyms: Uroxatral; Xatral
Dosage Forms: TABLET (EXTENDED-RELEASE)
Absorption: Absorption is 50% lower under fasting conditions
Interactions: Interactions for Alfuzosin:
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between Alfuzosin and other alpha-blockers have not been determined. However, interactions may be expected, and Alfuzosin should NOT be used in combination with other alpha-blockers.
Chemical IUPAC Name: N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]tetrahydrofuran-2-carboxamide
Chemical Formula: C19H27N5O4
Half Life: 10 hours
Drug Type: Approved Drug
# Accession No: APRD00490
CAS Registry Number: 81403-80-7
|
|
|
|
|
|
Alfuzosin News
(When available)
MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA Dec 7, 2005
The Journal of Pharmacy Technology Therapeutic agents evaluated include α-adrenergic antagonists (prazosin, terazosin, doxazosin, alfuzosin, tamsulosin) and 5-α-reductase inhibitors ...
The Doctor's Choice Awards Dec 9, 2005
Medgadget.com, ...categories. Sanofi-Aventis won for Lantus (insulin) in the diabetes category and for Uroxatral (alfuzosin) in urologicals. Wyeth ...
|
|
|
